Singapore has approved a second oral antiviral drug for treating COVID-19. Molnupiravir, branded as Lagevrio, was granted interim authorization under the Pandemic Special Access Route (PSAR) by the Health Sciences Authority (HSA) on April 19. The medicine was approved for treating mild to moderate COVID-19 patients aged 18 and above, who are at risk of…